What Is Mycotoxin Testing

Mycotoxin testing is a laboratory analysis that measures toxic compounds produced by certain mold species (such as Aspergillus, Stachybotrys, Penicillium, and Fusarium) in a person's urine or blood. These toxins, called mycotoxins, can accumulate in body tissues after exposure through inhalation, skin contact, or ingestion of contaminated food. The test identifies specific mycotoxin metabolites to help determine whether fungal toxin exposure may be contributing to a person's symptoms.

Mycotoxins are among the most biologically active environmental toxins humans encounter. They are small, lipophilic molecules that can cross cell membranes, accumulate in fatty tissue, and interfere with cellular processes including protein synthesis, mitochondrial function, and immune regulation. Chronic low-level exposure, particularly from living or working in water-damaged buildings, has been associated with a constellation of symptoms including fatigue, cognitive impairment, respiratory dysfunction, and heightened inflammatory markers. Because these symptoms overlap with many other conditions, mycotoxin exposure frequently goes unidentified.

From a longevity perspective, sustained mycotoxin burden places ongoing stress on detoxification pathways, increases oxidative damage, and may accelerate biological aging through chronic immune activation. Identifying and addressing mycotoxin exposure removes a persistent source of inflammation and cellular stress that can undermine other health optimization efforts. Testing provides an objective data point in what is otherwise a difficult diagnostic landscape, allowing targeted intervention rather than symptom management alone.

Most mycotoxin testing uses urine as the sample matrix because the kidneys are a primary route of mycotoxin excretion. The collected urine is analyzed using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) or enzyme-linked immunosorbent assay (ELISA). LC-MS/MS is generally considered more reliable because it can distinguish between structurally similar compounds with greater specificity. The panel typically screens for a defined set of mycotoxins, commonly including ochratoxin A, aflatoxin metabolites (such as aflatoxin M1), trichothecenes, gliotoxin, mycophenolic acid, citrinin, and zearalenone.

Some practitioners use a provocation protocol before urine collection, administering glutathione (orally or intravenously) or recommending a sauna session in the hours before the test. The rationale is that mycotoxins stored in adipose tissue and intracellular compartments may be mobilized into circulation and subsequently excreted in higher concentrations, improving detection sensitivity. This approach remains debated, as controlled studies comparing provoked and unprovoked collections in the same individuals are limited. Supporters argue it reduces false negatives; skeptics note it may produce results that are harder to interpret without established provoked reference ranges.

After analysis, results are reported as concentrations of each mycotoxin, typically in parts per billion, alongside reference ranges that represent typical values in presumably unexposed populations. Elevated levels of one or more mycotoxins suggest significant exposure, though the clinical threshold at which a given concentration produces symptoms varies among individuals depending on genetics, detoxification capacity, and total toxic burden. Results are most meaningful when interpreted alongside environmental testing data and clinical history.

A standard mycotoxin panel measures the concentration of specific fungal metabolites excreted in urine. The most commonly tested analytes include ochratoxin A (produced by Aspergillus and Penicillium species), aflatoxin metabolites such as aflatoxin M1 (from Aspergillus flavus and parasiticus), trichothecenes including satratoxin and roridin E (from Stachybotrys and Fusarium), gliotoxin (from Aspergillus fumigatus), mycophenolic acid (from Penicillium species), citrinin (from Penicillium and Aspergillus), and zearalenone (from Fusarium species).

Each of these mycotoxins exerts distinct biological effects. Ochratoxin A is nephrotoxic and immunosuppressive. Aflatoxins are potent hepatotoxins and recognized carcinogens. Trichothecenes inhibit protein synthesis at the ribosomal level. Gliotoxin suppresses immune cell function, particularly neutrophils and macrophages. Zearalenone mimics estrogen and can disrupt hormonal signaling. The panel essentially provides a chemical fingerprint of which mold species a person has been exposed to and which toxic mechanisms may be active.

Results are reported in parts per billion (ppb) or micrograms per liter, with each analyte compared against a reference range derived from presumably healthy, unexposed populations. Some laboratories also provide a creatinine-corrected value to account for urine concentration differences between samples.

Collection protocols vary depending on the laboratory and the practitioner's preference regarding provocation. For a standard unprovoked collection, use the first morning urine, which is the most concentrated and provides the highest sensitivity for detecting excreted mycotoxins. Avoid excessive fluid intake the evening before, as dilute urine can reduce analyte concentrations below detection thresholds.

If a provocation protocol is recommended, this typically involves taking oral or liposomal glutathione (500 to 1000 mg) the evening before and morning of collection, sometimes combined with a 20 to 30 minute sauna session to mobilize fat-stored mycotoxins into circulation. Some practitioners also recommend a brief fast before collection. Whichever approach is used, document the protocol precisely so that any follow-up testing can replicate the same conditions, allowing valid comparison over time. The urine sample is collected in a provided container and shipped to the laboratory according to kit instructions, usually with a cold pack to preserve sample integrity.

Results are presented as measured concentrations of each mycotoxin alongside laboratory reference ranges. Values within the reference range suggest either no significant exposure or effective clearance. Values above the reference range indicate that the body is excreting higher-than-typical levels of that specific mycotoxin, which may reflect ongoing or recent exposure. Multiple elevated analytes pointing to different mold species can suggest either multiple environmental sources or a heavily contaminated environment harboring several species.

Context matters considerably in interpretation. A single mildly elevated ochratoxin A result in someone who drinks large amounts of wine and coffee may reflect dietary intake rather than environmental mold exposure. Conversely, a negative result in someone with strong clinical suspicion and known water-damaged building exposure could reflect impaired excretion rather than absence of exposure; some practitioners will follow up with a provoked retest. The pattern of which mycotoxins are elevated can help guide environmental investigation, since Stachybotrys (producing trichothecenes and satratoxins) is strongly associated with water-damaged building materials, while Aspergillus (producing ochratoxin A, gliotoxin, and aflatoxins) is more ubiquitous.

Repeat testing after a period of treatment and environmental remediation serves as the most clinically useful application. A meaningful decline in mycotoxin levels over weeks to months, combined with symptom improvement, supports the diagnosis and validates the intervention.

An initial baseline test is appropriate when mycotoxin exposure is suspected based on symptoms and exposure history. If results are elevated and treatment is initiated (binders, detoxification support, environmental remediation), a follow-up test is typically performed three to six months later to assess whether mycotoxin levels are declining. The exact interval depends on the severity of initial results, the pace of remediation, and clinical response.

Once levels have normalized and symptoms have resolved, routine retesting is unnecessary unless new symptoms emerge, a new water damage event occurs, or the person moves to a different environment where exposure may resume. For individuals with known genetic susceptibility to impaired mycotoxin clearance (such as certain HLA-DR haplotypes associated with mold sensitivity), periodic monitoring every 12 to 18 months may be reasonable as a surveillance measure, particularly if the person lives in a humid climate with higher mold prevalence.

The scientific literature on mycotoxin exposure and human health spans several decades, though much of it originates from occupational health and food safety contexts rather than residential mold exposure. Animal studies have established clear dose-response relationships for many mycotoxins, demonstrating immunosuppression, hepatotoxicity, nephrotoxicity, and carcinogenicity at various concentrations. Epidemiological studies of populations living in water-damaged buildings consistently show higher rates of respiratory illness, neurological complaints, and inflammatory markers compared to controls, though isolating mycotoxins from other mold-related exposures (such as beta-glucans and volatile organic compounds) is difficult in these settings.

The specific validity of urinary mycotoxin testing as a clinical tool remains debated within the medical community. Mainstream medical organizations have not yet endorsed routine mycotoxin urine panels, citing limited reference range data, lack of standardization across laboratories, and the absence of large controlled trials linking specific urinary mycotoxin concentrations to defined clinical outcomes. Functional and environmental medicine practitioners counter that the clinical utility is demonstrated by the correlation between elevated results, known exposure, and symptomatic improvement after targeted treatment. Studies comparing different laboratory methods have shown reasonable agreement for some analytes and poor concordance for others, highlighting the importance of laboratory selection. The evidence base is strongest for ochratoxin A and aflatoxins, where validated analytical methods and toxicological data are most developed.

Mycotoxin testing carries minimal physical risk since it requires only a urine sample. The primary concern is interpretive: results may be influenced by recent dietary mycotoxin intake (from grains, coffee, wine, or cheese), provocation protocols that lack standardized reference ranges, and inter-laboratory variability in methodology and reporting. False negatives can occur if mycotoxin excretion is low at the time of collection due to impaired detoxification, sequestration in tissues, or insufficient mobilization. False positives, or clinically insignificant elevations, may result from normal dietary exposure being flagged against overly conservative reference ranges. Results should be interpreted by a practitioner with experience in environmental medicine, and ideally paired with environmental testing and clinical context rather than treated as a standalone diagnostic.